Mechanistically, miR-184 targeted factor inhibiting hypoxia-inducible factor 1 (FIH-1), which in turn stabilised hypoxia-inducible factor 1-alpha (HIF-1α) and promoted tumour progression. Here, HIF1A is linked to neoplasm.